Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the
COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Medicines Agency (EMA) has granted access to its priority medicines (PRIME) scheme for MVA-BN® RSV in active immunization for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults ≥60 years of age. There are no approved vaccines for RSV, and access to PRIME has been granted upon an assessment that the available clinical data overall show
(Bloomberg) -- Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.Most Read from BloombergChina Says It May Have Detected Signals From Alien CivilizationsStocks Jump as Powell Soothes Wall Street’s Nerves: Markets WrapFed Hikes 75 Basis Points; Powell Says 75 or 50 Likely in JulyWorld’s Central Banks Got It Wrong, and Economies Pay the PriceAmericans Are Building Vacation-Home Empires